A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Phase of Trial: Phase III
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Eflornithine (Primary) ; Sulindac
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms PACES
- 11 Apr 2016 Planned End Date changed from 1 Jul 2019 to 1 Jun 2029.
- 11 Apr 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jun 2024.
- 29 May 2015 Trial design presented at 51st Annual Meeting of the American Society of Clinical Oncology.